Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
The purpose of this study is to assess the safety and effectiveness of different combinations of drugs to treat advanced clear cell renal cell carcinoma, a type of kidney cancer, in patients who have not received any prior treatment or who have recently developed worsening disease while receiving immunotherapy that targets the PD-1/PD-L1 proteins.
However, SBRT may not be enough for people with intermediate-risk prostate cancer and unfavorable genetic features. These features may make it more likely that the cancer will come back after radiation therapy. These people may benefit from SBRT with hormonal therapy early in their care.
Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the best treatments for prostate cancers that have metastasized (spread). The benefits of hormone treatments often do not last, however. Over time, many prostate cancers keep growing even with hormonal therapies. These are called castration-resistant prostate cancers (CRPC).
In this study, researchers are assessing the drug asciminib for people who recently learned they have chronic myeloid leukemia (CML). They will take it twice a day. If after two years they do not respond well to asciminib, they may take the drug nilotinib with asciminib.
Prostate removal (prostatectomy), a treatment for prostate cancer, can cause urinary incontinence (the inability to control the flow of urine). People experience urinary incontinence in the days immediately following surgery, which can reduce quality of life. Most people experience urinary incontinence for several weeks to months after surgery, but it can last longer.
The purpose of this study is to see whether the combination of melphalan, BCNU, vitamin B12b, and vitamin C, followed by autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer who have a BRCA1 and/or BRCA2 gene mutation. All of these treatments are given intravenously (by vein).
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
Researchers are finding the best dose of MB-CART19.1 immunotherapy in people with lymphoma. The people in this study have central nervous system lymphoma (CNSL) that came back or keeps growing after treatment.
